Apotex Health Corp. (TSX:APTX)
Canada · Delayed Price · Currency is CAD | Market Cap | 7.05B |
| Revenue (ttm) | 3.20B +4.2% |
| Net Income | -27.27M |
| EPS | -0.16 |
| Shares Out | 229.03M |
| PE Ratio | n/a |
| Forward PE | 15.04 |
| Dividend | 0.20 (0.65%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 242,303 |
| Open | 30.70 |
| Previous Close | 30.54 |
| Day's Range | 30.27 - 30.89 |
| 52-Week Range | 26.05 - 40.18 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 41.37 (+34.36%) |
| Earnings Date | Nov 12, 2026 |
About Apotex Health
Apotex Health Corp. operates as a pharmaceutical manufacturing company in Canada, the United States, Mexico, and India. The company develops, manufactures, and distributes a broad portfolio of prescription and generic pharmaceuticals, oncology biosimilar pharmaceuticals, branded specialty pharmaceuticals, and branded consumer health and wellness products. It operates through three business lines including conventional generic pharmaceuticals; specialty generic pharmaceuticals; and brands & biosimilars. The company has a a strategic partnership ... [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2026, Apotex Health's revenue was 3.49 billion, an increase of 4.21% compared to the previous year's 3.35 billion. Earnings were 373.78 million, an increase of 146.39%.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for APTX stock is "Strong Buy." The 12-month stock price target is $41.37, which is an increase of 34.36% from the latest price.
News
Apotex Health Earnings Call Transcript: Q1 2027
Q1 fiscal 2027 results were slightly above expectations, with revenue up 2% year-over-year (ex-VLLP), strong Canadian growth, and robust launch execution. Guidance for the year targets upper mid-single-digit revenue growth and a 30% adjusted EBITDA margin, supported by new product launches and portfolio expansion.
Apotex Health Earnings release: Q1 2027
Apotex Health released its Q1 2027 earnings on August 12, 2026, summarizing the period's financial results.
Apotex Health Report: Q1 2027
Apotex Health published a report on August 12, 2026 containing material business information for investors and shareholders.
Apotex Health MD&A: Q1 2027
Apotex Health filed a regulatory document on August 12, 2026 disclosing important business information.
Apotex Health Slides: Q1 2027
Apotex Health has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 12, 2026.
Apotex Health initiated with a Buy at Canaccord
Canaccord analyst Tania Armstrong-Whitworth initiated coverage of Apotex Health (APTX.TO) with a Buy rating and C$42 price target The conventional generics manufacturer has been transforming its busin...
Apotex Health initiated with an Outperform at Raymond James
Raymond James analyst Michael Freeman initiated coverage of Apotex Health (APTX.TO) with an Outperform rating and C$36 price target
Apotex Health initiated with an Outperform at National Bank
National Bank initiated coverage of Apotex Health (APTX.TO) with an Outperform rating and C$43 price target
Apotex Health initiated with a Buy at Jefferies
Jefferies analyst Dennis Ding initiated coverage of Apotex Health (APTX.TO) with a Buy rating and C$40 price target Apotex is a high-quality, diversified global specialty pharmaceutical company, with ...
Apotex Health initiated with an Outperform at ATB Cormark
ATB Cormark initiated coverage of Apotex Health (APTX.TO) with an Outperform rating and C$40 price target
Apotex Health initiated with a Buy at Desjardins
Desjardins analyst Gary Ho initiated coverage of Apotex Health (APTX.TO) with a Buy rating and C$40 price target Apotex holds about 23% of the Canadian generic market and demand is…
Apotex Health initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Apotex Health (APTX.TO) with a Buy rating and C$40 price target Apotex is a leading generics company anchored in Canada where its dominance hedges against…
Apotex Health initiated with a Buy at Stifel
Stifel initiated coverage of Apotex Health (APTX.TO) with a Buy rating and C$42 price target Apotex is leveraging its domestic dominance and leading Canadian Generic drug share of 23% into…
Apotex Health initiated with an Outperformer at CIBC
CIBC initiated coverage of Apotex Health (APTX.TO) with an Outperformer rating and C$40 price target
Apotex Health initiated with an Outperform at Scotiabank
Scotiabank initiated coverage of Apotex Health (APTX.TO) with an Outperform rating and C$40 price target Apotex Health’s Journey of Health strategy remains underappreciated in the current valuation, s...
Apotex Health initiated with an Outperform at RBC Capital
RBC Capital analyst Douglass Miehm initiated coverage of Apotex Health (APTX.TO) with an Outperform rating and C$43 price target As leader in the attractive Canadian generic industry with 23% share…
Apotex Health initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Apotex Health (APTX.TO) with an Outperform rating and C$39 price target citing the company’s number-one position in the Canadian generic/specialty pharma market and “...